JGH

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Retrieved on: 
Tuesday, November 28, 2023
Associate, Metastasis, Therapeutic endoscopy, Partnership, Neoplasm, Division, Death, Alpha Sigma Tau, Lung, Research, Breast, Radiation, General Hospital, Data, Pancreas, Alpha, Brain, Vulva, JGH, Endoscopy, Clinical trial, News, FRCPC, Pancreatic cancer, CA19-9, Radiation therapy, Interim, Assistant, McGill University, Translational research, Medical school, Patient, Safety, Neck

JERUSALEM, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the release of interim results from treatment of the first five patients in the Company’s safety and feasibility trial examining the use of Alpha DaRT to treat advanced pancreatic cancer, currently underway at two university hospitals in Montreal, Canada.

Key Points: 
  • Tumor stages of the treated patients ranged from stage II to stage IV, and treated tumors were located in the pancreatic head or neck.
  • With respect to primary outcome measures, the Alpha DaRT procedure was deemed technically successful in all five cases, with Alpha DaRT sources successfully inserted into the target tumor.
  • The first two patients, who had received the fewest number of Alpha DaRT sources, both died approximately three months after treatment, and the deaths were not related to Alpha DaRT treatment.
  • The study primarily examines the safety and feasibility of placing the Alpha DaRT sources in the tumor utilizing endoscopic ultrasound, and the overall safety of the procedure by measuring adverse events.

U.S. Court of Appeals for the Second Circuit Upholds that Nuveen-Advised Closed-End Funds Violated the Investment Company Act of 1940

Retrieved on: 
Friday, December 1, 2023
Finance, Consulting, Banking, Professional Services, Asset Management, NYSE, JSD, Policy, JRO, Appellate court, Amendment, Boaz Weinstein, Trustee, JGH, NSL, District court, Person, Judgement, JFR, Oaktree Capital Management, Financial adviser, Security (finance), Nuveen

The District Court subsequently issued a summary judgment ruling in favor of Saba and invalidated the actions of Nuveen and the Funds’ trustees.

Key Points: 
  • The District Court subsequently issued a summary judgment ruling in favor of Saba and invalidated the actions of Nuveen and the Funds’ trustees.
  • The Court’s decision on November 30, 2023, upholds the District Court’s ruling that Nuveen’s practice of vote stripping is unlawful.
  • Boaz Weinstein, Founder and Chief Investment Officer of Saba, commented:
    “Federal law is unambiguous in the protections it provides shareholders.
  • These Funds’ trustees, who are clearly unfit to serve as fiduciaries, should resign immediately and never again serve on boards.

Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial

Retrieved on: 
Monday, April 3, 2023
Pancreatic cancer, Endoscopy, Partnership, Medical school, Alpha Sigma Tau, Pancreatic tumor, Jewish General Hospital, Alpha, Neoplasm, JGH, Breast, Brain, Research, Radiation therapy, Assistant, Lung, Therapeutic endoscopy, HIV disease progression rates, Patient, General Hospital, Division, Translational research, McGill University, CA19-9, FRCPC, Rollcage Stage II, Vulva, III, Safety, Metastasis, Disease, Medical imaging, Cancer, MD, Gastroenterology, Medicine

JERUSALEM, April 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with advanced inoperable pancreatic cancer has been treated in a feasibility and safety study of Alpha DaRT at the Jewish General Hospital (“JGH”) in Montreal, Canada, which is an affiliated teaching hospital of McGill University, Faculty of Medicine.

Key Points: 
  • The study will primarily examine the safety and feasibility of placing the Alpha DaRT sources in the tumor utilizing endoscopic ultrasound, and the overall safety of the procedure by measuring adverse events.
  • With the Alpha DaRT technology and our expertise in developing novel advanced endoscopic techniques, we are thrilled to offer patients with inoperable advanced pancreatic cancer an innovative therapeutic option.
  • We hope that the Alpha DaRT treatment will offer better outcomes to these patients with such a challenging disease.
  • We appreciate the unconditional support from Alpha Tau and the MCTRC who worked together to eliminate any barriers for opening this trial at our hospital and for securing a straightforward procedure for Alpha DaRT insertion into the pancreatic tumor.”

Nuveen Global High Income Fund Announces Update to Portfolio Management Team

Retrieved on: 
Tuesday, March 21, 2023
Professional Services, Finance, Columbia University, Mattel, Fordham University, University, CFA, Indian Sugar Mills Association, Engineering, Policy, JGH, Emerging market debt, Yale school, Research, Columbia Business School, Asset, Nuveen, NYSE, Citywire, CFA Institute, International business, Investment, Female, Security (finance), Manhattan College, Economics

Effective immediately, portfolio manager responsibilities for Nuveen Global High Income Fund (NYSE: JGH) have been updated.

Key Points: 
  • Effective immediately, portfolio manager responsibilities for Nuveen Global High Income Fund (NYSE: JGH) have been updated.
  • Mr. Persson will continue in his role at Nuveen as Chief Investment Officer of Nuveen Global Fixed Income.
  • John Espinosa oversees all investment research across Nuveen’s global fixed income team.
  • Brenda Langenfeld is a portfolio manager for Nuveen’s global fixed income team and a member of the preferred securities sector team.

Jewish General Hospital Foundation launches $5M COVID-19 Campaign: Three Quebec women are leading the way with gifts totalling $1.3M

Retrieved on: 
Tuesday, April 21, 2020
Articles, Côte-des-Neiges–Notre-Dame-de-Grâce, Jewish General Hospital, JGH, Culture, Hospital, Proverb, Health

"In our tradition, we believe strongly in the proverb - Give amanafishand you feedhimfor a day;teach a man to fishand you feedhimfor a lifetime.

Key Points: 
  • "In our tradition, we believe strongly in the proverb - Give amanafishand you feedhimfor a day;teach a man to fishand you feedhimfor a lifetime.
  • "I honestly believe in this idea, and if the community likes it too, I ask that they give generously.
  • "The Jewish General Hospital is one of the top Hospitals in Quebec, and when they informed me of these projects, I immediately decided to get involved.
  • Since 1969, the Jewish General Hospital Foundation has led a dynamic fundraising program in support of the Jewish General Hospital (JGH), one of the province's largest and busiest acute-care hospitals.

Sophie Desmarais donates $500,000 to COVID-19 research at the Jewish General Hospital, urges those who can to "donate generously"

Retrieved on: 
Friday, March 27, 2020
Côte-des-Neiges–Notre-Dame-de-Grâce, Jewish General Hospital, JGH, Hospital, Health

"The Jewish General Hospital is one of the top Hospitals in Quebec, and when they informed me of these projects, I immediately decided to get involved.

Key Points: 
  • "The Jewish General Hospital is one of the top Hospitals in Quebec, and when they informed me of these projects, I immediately decided to get involved.
  • I am compelled to support our hometown research expertise in the face of this global epidemic," stated Ms. Desmarais when asked why she chose to support the JGH and COVID research in particular.
  • We need to come together and support the exceptional efforts made by medical professionals and researchers.
  • Since 1969, the Jewish General Hospital Foundation has led a dynamic fundraising program in support of the Jewish General Hospital (JGH), one of the province's largest and busiest acute-care hospitals.